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AbsTrACT
Objective To assess clinical, electrophysiological and 
whole-body muscle MRI measurements of progression 
in patients with motor neuron disease (MND), as tools 
for future clinical trials, and to probe pathophysiological 
mechanisms in vivo.
Methods a prospective, longitudinal, observational, 
clinicoelectrophysiological and radiological cohort study 
was performed. Twenty-nine patients with MND and 22 
age-matched and gender-matched healthy controls were 
assessed with clinical measures, electrophysiological 
motor unit number index (MUNIX) and T2-weighted 
whole-body muscle MRI, at first clinical presentation 
and 4 months later. Between-group differences and 
associations were assessed using age-adjusted and 
gender-adjusted multivariable regression models. 
Within-subject longitudinal changes were assessed using 
paired t-tests. patterns of disease spread were modelled 
using mixed-effects multivariable regression, assessing 
associations between muscle relative T2 signal and 
anatomical adjacency to site of clinical onset.
results patients with MND had 30% higher relative 
T2 muscle signal than controls at baseline (all regions 
mean, 95% cI 15% to 45%, p<0.001). higher T2 signal 
was associated with greater overall disability (coefficient 
−0.009, 95% cI −0.017 to –0.001, p=0.023) and 
with clinical weakness and lower MUNIX in multiple 
individual muscles. Relative T2 signal in bilateral tibialis 
anterior increased over 4 months in patients with MND 
(right: 10.2%, 95% cI 2.0% to 18.4%, p=0.017; left: 
14.1%, 95% cI 3.4% to 24.9%, p=0.013). anatomically, 
contiguous disease spread on MRI was not apparent in 
this model.
Conclusions Whole-body muscle MRI offers a new 
approach to objective assessment of denervation over 
short timescales in MND and enables investigation of 
patterns of disease spread in vivo. Muscles inaccessible 
to conventional clinical and electrophysiological 
assessment may be investigated using this methodology.
INTrOduCTION
A major barrier to effective therapeutics in motor 
neuron disease/amyotrophic lateral sclerosis 
(MND/ALS) is the lack of an objective measure of 
disease progression over short timescales that mini-
mise expense in the context of clinical trials.1 A 
recent systematic review of MRI in MND reported 
116 clinical studies, all of which investigated the 
central nervous system (CNS).2 Muscle denervation 
is a major clinical feature of MND and results in 
fluid shifts detectable as altered T2 signal character-
istics3 that, in contrast to clinical assessments, are 
independent of participant’s effort and premorbid 
abilities. Whole-body MRI now enables sampling 
of multiple body regions during a single examina-
tion within acceptable timescales, including muscles 
inaccessible to conventional clinical or electrophys-
iological assessment. However, very few previous 
muscle MRI studies in MND exist,4–7 and none has 
assessed multiple body regions.
This is the first study to apply whole-body muscle 
MRI to patients with MND, who also underwent 
detailed longitudinal, clinical and electrophysiolog-
ical phenotyping. The objective was to address the 
problem of anatomical phenotypic heterogeneity, 
which has represented a barrier to developing effec-
tive CNS imaging biomarkers, by adopting a muscle 
sampling methodology analogous to diagnostic El 
Escorial criteria.8 We hypothesised that (1) patients 
with MND would exhibit higher relative muscle T2 
signal than healthy controls; (2) high relative muscle 
T2 signal would correlate with clinical weakness 
and lower electrophysiological motor unit number 
indices; (3) relative muscle T2 signal in patients 
with MND, but not controls, would increase over 
time and (4) changes in MRI parameters could be 
applied to probe pathophysiological mechanisms in 
vivo to model whether disease spread was anatom-
ically contiguous.
PATIeNTs ANd MeThOds
study population and data collection
This was a prospective, longitudinal, observational 
cohort study. Consecutive patients were recruited 
at first presentation to the tertiary referral neuro-
muscular clinic at the Royal Hallamshire Hospital, 
Sheffield, UK. Inclusion criteria were age 18 years 
or over, a clinical diagnosis of MND fulfilling 
clinically possible, probable or definite revised El 
Escorial criteria8 or progressive muscular atrophy 
(defined as a pure lower motor neuron syndrome 
at study entry). Exclusion criteria were inability to 
give informed consent, a contraindication to MRI, 
coexistent neuromuscular disease, pregnancy or 
respiratory failure impairing ability to lie flat in 
the scanner. Healthy age-matched and sex-matched 
volunteers were recruited from spouses and friends 
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of patients, via advertisement, and from clinical and research 
staff. The primary outcome measure was comparison of relative 
T2 signal on MRI between groups. In order to satisfy the require-
ment of at least 10–20 observations per degree of freedom for 
the linear regression models9 (with age and gender as predictors), 
a minimum sample size of 30–60 observations was required.
Clinical, electrophysiological and neuroimaging assessments 
and analysis
Patients underwent clinical assessments and all participants 
underwent electrophysiological and imaging assessment at base-
line and 4 months, on the same day. Four months were chosen 
pragmatically as a minimal interval to observe clinical change 
and minimise cohort attrition and informed by the only previous 
similar study.5 Age, gender, date and site of onset of symptom-
atic weakness were recorded. Patients completed the revised 
amyotrophic lateral sclerosis functional rating scale-revised 
(ALSFRS-R),10 a 48-point score, with lower scores indicating 
greater impact of MND on daily function. The following muscle 
groups were assessed and graded from 0 to 5 on the Medical 
Research Council (MRC) scale11 bilaterally: shoulder abduc-
tors, elbow flexors and extensors, wrist extensors and flexors, 
abductor pollicis brevis, hip flexors, knee flexors and extensors, 
ankle dorsiflexors, neck flexors and neck extensors, resulting in 
a maximum score of 110 with lower scores indicating greater 
weakness. Handheld dynamometry was performed in ankle 
dorsiflexors, after validation in a practice cohort, according to 
the established protocols.12 All participants were weighed on the 
same scales at each visit.
At each visit, maximum compound muscle action potential 
(CMAP) and motor unit number index (MUNIX) estimates13 
were obtained from the least clinically affected side (to avoid 
‘floor’ effects) in biceps and tibialis anterior (TA), using a Dantec 
Keypoint electromyography machine (Natus Medical, Pleas-
anton, California, USA), following internationally agreed proto-
cols.14 Motor unit size (MUSIX) parameters were calculated as 
the ratio of CMAP to MUNIX; higher scores are associated with 
reinnervation.15
MRI was performed at 3 T (Ingenia 3.0T, Philips Healthcare, 
Best, the Netherlands). T2-weighted fast spin echo (repetition 
time (TR)=1107 ms, effective echo time (TE)=80 ms, interpo-
lated voxel size=0.78×0.78×5 mm3) whole-body images were 
acquired in the coronal plane at six anatomical stations (Philips 
Healthcare). Acquisition time was 55 s per station and approx-
imately 6 min total scan time (excluding localisers and breath-
holds during thoracic and abdominal acquisitions).
Regions of interest were contoured manually according to 
the standardised anatomical landmarks (see online supplementary 
file 1) on single unprocessed coronal slices, in line with previous 
studies,16 using a semiautomated spline function provided in the 
system manufacturer’s online workstation (Extended MR Work-
space V.2.6.3.5, Philips Healthcare). Intrarater and inter-rater 
reproducibility was first confirmed by two independent raters, 
who achieved coefficients of variation <5% for all regions of 
interest on six practice datasets at least 24 hours apart. Final 
contouring was performed by a single blinded operator (TMJ) 
and mean T2 signal estimates were derived for the tongue, right 
and left biceps, right and left thoracic paraspinals, right and 
left anterolateral leg compartment encompassing TA, second 
cervical vertebral body, right humerus and right tibia. Individual 
anterolateral leg compartment muscle boundaries are not readily 
distinguishable on coronal MR5 but TA predominates and is used 
for brevity for the remainder of this manuscript. Muscle region 
of interest T2 values were expressed relative to those obtained 
from bone within the same station (tongue:second cervical verte-
bral body, biceps:humerus, paraspinals:humerus and TA:tibia). 
A mean paraspinal muscle estimate was used for all analyses 
except where otherwise specified, in order for the thoracic 
domain to be represented by a single parameter, in accordance 
with El Escorial criteria.8 All scans were reviewed by a consultant 
neuroradiologist (NH) and incidental findings reported back to 
study participants.
statistical analysis
Statistical analysis was performed in Stata V.13.1 and SAS/STAT 
V.9.3.
Patients versus controls at baseline
Independent binomial rate score-based CIs were used to assess 
for between-group gender differences. For continuous variables, 
between-group differences were assessed using multiple linear 
regression, entering each clinical, electrophysiological and MRI 
measure of interest, in turn, as response variables and patient/
control group indicator, age and gender as predictor variables. 
For electrophysiological variables, the side tested was entered as 
an additional predictor.
Associations between muscle MRI and clinicoelectrophysiological 
measures
Associations between baseline clinical, electrophysiological and 
imaging parameters were assessed using regression models. 
Age, gender, days from symptom onset, ALSFRS-R and MRC 
summary score were each regressed, in turn, against whole-body 
relative T2 signal. Individual muscle MRC scores in biceps and 
TA and dynamometry in TA were each regressed, in turn, against 
the corresponding individual muscle relative T2 values. For elec-
trophysiological parameters, the side tested was always regressed 
against the clinical or radiological parameter of corresponding 
laterality, entering the side tested as an additional predictor vari-
able. Site of onset (leg, arm or bulbar) was specified as a binary 
variable and regressed against relative T2 signal from the corre-
sponding anatomical region. Age and gender were entered into 
all models as additional predictor variables. Parameter estimates 
were reported for unadjusted models, and p values reported for 
both unadjusted and adjusted models.
Associations between each of the clinical parameters and 
MUNIX were also assessed, in turn, using the same method-
ology, always entering the side tested as an additional predictor 
variable.
Longitudinal changes
Within-group differences between time points were reported 
using two-tailed paired t-tests. The percentage of patients with 
a change in clinical and radiological measures was reported. To 
assess whether radiological changes were only found in muscles 
becoming clinically weak, correlation analysis assessing associa-
tions between changes in radiological parameters and changes 
in clinical parameters was performed. The percentage of slow 
clinical progressors, defined as a change in ALSFRS-R of one 
point or less, exhibiting radiological changes was reported. 
The responsiveness of each clinical, electrophysiological and 
radiological measure to change was assessed using standardised 
response means (mean/SD of measured change).16
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Modelling disease spread
Anatomical patterns of disease spread from site of clinical onset 
in patients with MND were investigated by first calculating esti-
mates of relative T2 signal change in each muscle, expressed 
as a ratio of 4 months to baseline measurements, natural log 
transformed, for each of the body regions, in turn: tongue, 
right biceps, left biceps, right thoracic paraspinal, left thoracic 
paraspinal, right TA and left TA. A distance variable was then 
created for each muscle in each patient, representing step changes 
in anatomical adjacency to site of clinical onset, at the level of the 
anterior horn cells supplying each muscle. The muscle of clinical 
onset (which was tongue, right arm, left arm, right leg, left leg, 
both arms or both legs) was allocated zero. Adjacent anatomical 
regions to the site of clinical onset were allocated one, consid-
ering both ‘horizontal’ anatomical organisation (eg, right leg to 
left leg) and ‘vertical’ organisation (ie, cranial to caudal along 
the neuroaxis, eg, right arm to right thoracic paraspinal or right 
thoracic paraspinal to right leg). If regions were two steps apart, 
they were allocated two (eg, tongue and right paraspinal). If 
regions were three steps apart, they were allocated three (eg, 
right arm and left leg). This distance variable was entered as an 
ordinal predictor into a mixed effects linear regression model 
with change in relative muscle T2 signal as the response variable, 
adjusting for baseline T2 muscle signal at baseline and including 
subject as a random effect.
Muscle area
A post hoc analysis was performed to assess differences in 
area for each muscle assessed. Intrarater and inter-rater repro-
ducibility <5% was first achieved and then the entire muscle 
contoured. Baseline differences between patients and controls 
and longitudinal changes over time were assessed, using the same 
statistical methodology applied to investigate relative T2 signal, 
described in preceding sections.
For all analyses, statistical significance was reported at 
p<0.05 and a false discovery rate approach was used to correct 
for multiple comparisons.17
resulTs
Twenty-nine patients with MND and 22 healthy volunteers 
were recruited between October 2013 and May 2016 (figure 1). 
Groups were well matched for age, gender and weight (table 1). 
Twenty-six patients had ALS (six clinically definite, 12 clinically 
probable and eight clinically possible) and three had progres-
sive muscular atrophy. Limb onset occurred in 25 patients (five 
right arm, seven left arm, two both arms, four right leg, five 
Figure 1 Flow chart of patients’ assessment and dropout. MND, motor 
neuron disease; MUNIX, motor unit number index. 
Table 1 Demographic, clinical, electrophysiological and neuroimaging baseline characteristics
Patients (n=29) Controls (n=22) difference, patients >controls (95% CI) P value
Mean age, years (SD) 57.1 (13.5) 54.2 (15.7) 3.0 (−5.3 to 11.1) 0.474
Gender 7 (24.1%) females 9 (40.9%) females −16.8% (−42.2% to 9.3%) 0.207
Mean weight, kg (SD) 77.7 (15.3) 75.0 (15.1) 2.7 (−6.1 to 11.4) 0.540 (0.746)
Median weeks from symptom onset (range) 66 (25–265)
Mean MRC score (SD) 100/110 (10.6)
Mean ALSFRS-R (SD) 40/48 (4.5)
Mean MuNIX biceps (sd) 129.3 (53.9) 200.2 (85.8) −71.0 (−112.6 to –29.3) 0.001 (<0.001)
Mean CMAP biceps, mV (sd) 5.5 (2.2) 7.9 (3.4) −2.3 (−4.0 to –0.7) 0.007 (0.002)
Mean MUSIX biceps (SD) 41.4 (9.6) 39.6 (4.1) 1.7 (−2.9 to 6.3) 0.459 (0.990)
Mean MuNIX TA (sd) 83.5 (48.6) 139.3 (32.2) −55.8 (−80.6 to –30.9) <0.001 (<0.001)
Mean CMAP TA, mV (sd) 4.2 (1.9) 5.4 (3.7) −1.2 (−2.1 to –0.3) 0.002 (0.002)
Mean MusIX TA (sd) 56.4 (27.3) 39.7 (6.4) 16.7 (4.5 to 29.0) 0.009 (0.016)
MrI relative T2 signal summary score all 
regions (sd)
0.39 (0.10) 0.30 (0.04) 30.3% (15.0% to 45.5%) <0.001 (<0.001)
MRI relative T2 signal tongue (SD) 0.69 (0.13) 0.64 (0.09) 8.3% (−1.6% to 18.2%) 0.098 (0.082)
MrI relative T2 signal right biceps (sd) 0.38 (0.10) 0.30 (0.06) 25.2% (9.2% to 41.1%) 0.003 (0.003)
MrI relative T2 signal left biceps (sd) 0.19 (0.15) 0.12 (0.04) 62.6% (7.1% to 118.1%) 0.028 (0.034)
MrI relative T2 signal thoracic paraspinals (sd) 0.45 (0.17) 0.31 (0.09) 42.4% (16.9% to 68.0%) 0.002 (0.006)
MrI relative T2 signal right TA (sd) 0.38 (0.16) 0.27 (0.05) 37.6% (12.4% to 62.8%) 0.004 (0.011)
MrI relative T2 signal left TA (sd) 0.24 (0.15) 0.14 (0.05) 73.3% (26.4% to 120.1%) 0.003 (0.005)
Parameter estimates refer to unadjusted differences between patients and controls, with 95% CI in parentheses. Pvalues refer to differences between patients and controls 
unadjusted and, in parentheses, adjusted for age and gender. Relative T2 signal differences are reported as percentage differences in patients with motor neuron disease relative 
to controls. Significant results after correction for multiple comparisons are highlighted in bold.
ALSFRS-R, amyotrophic lateral sclerosis functional rating scale-revised; CMAP, compound muscle action potential; MRC, Medical Research Council; MUNIX, motor unit number 
index; MUSIX, motor unit size index; TA, tibialis anterior.
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left leg and two both legs) and bulbar onset in four patients. 
Patients were recruited at a relatively early stage of disease (mean 
ALSFRS-R score 40, mean MRC summary score 100/110 and 
median duration of symptoms 15 months). Patients’ assessments 
were repeated after a mean of 133 days (95% CI 125 to 142 
days) and controls 206 days (95% CI 172 to 239 days). Inci-
dental liver cysts were found in 8%, Baker’s cysts in 6% and 
joint effusions in 6% of participants. All liver cysts were benign 
on subsequent ultrasound imaging. The only clinically rele-
vant finding was a single patient with a leaking silicone breast 
implant. The patients’ clinical course was consistent with MND 
in all cases.
Patients versus controls at baseline
On baseline electrophysiology, patients with MND had lower 
MUNIX and CMAPs than controls in both TA and biceps 
(table 1). MUSIX was higher in patients’ TA. At baseline MRI 
assessment, patients had higher relative T2 signal than controls 
in all muscles except the tongue, in which there was a trend 
towards increased relative T2 signal in the patient group (table 1 
and figures 2 and 3).
Associations between muscle MrI and 
clinicoelectrophysiological measures
Higher relative muscle T2 signal was associated with greater 
weakness in each of the tested muscles on MRC scoring, except 
right biceps. Higher relative T2 signal was associated with 
greater weakness measured using dynamometry in TA bilat-
erally (table 2). Higher relative T2 signal was associated with 
lower MUNIX and CMAPs. Leg-onset disease was associated 
with higher relative T2 in TA (regression coefficients: right 
0.14 units (95% CI 0.03 to 0.25, p=0.013); left 0.14 units 
(95% CI 0.03 to 0.24, p=0.012)), but there were no associa-
tions in biceps or the tongue for arm and bulbar-onset disease, 
respectively.
Associations between MUNIX and clinical measures are 
reported in online supplementary table S1.
longitudinal changes
In healthy controls, there were no longitudinal changes in rela-
tive T2 signal or MUNIX in any muscle. Variability of relative 
T2 signal estimates within the control group is reported in online 
supplementary table S2.
Longitudinal changes in clinical, electrophysiological and 
MRI parameters in patients with MND were evident (table 3 
and figure 4). Clinical change was most evident in TA bilater-
ally. There was also a statistically significant decrease in MUNIX 
in TA. Relative T2 signal values increased significantly in both 
TA muscles in patients with MND with increases evident in 
73% and 82% of patients in right and left TA, respectively. This 
contrasted with decreases in power, which were evident in 45% 
and 59% of patients when measured using dynamometry and 
41% and 50% of patients when measured using MRC scores in 
right and left TA, respectively.
Moderate associations were found between increases in 
relative T2 signal and decreases in MRC scores in TA (right 
r=−0.63, p=0.002; left r=−0.50, p=0.017). No significant 
associations were found between changes in relative T2 signal 
and changes in dynamometry in TA.
Six of the 22 patients with MND with longitudinal follow-up 
were designated as slow progressors; two patients decreased by 
one point, two patients did not change and two patients exhib-
ited an increase of one point in ALSFRS-R. In this subgroup, 
mean relative T2 signal increases of 8.1% and 18.9% were seen 
Figure 2 Baseline data in patients and controls. The central panel shows illustrative central coronal slices from whole-body T2-weighted datasets obtained 
in a healthy control (left) and a patient with MND (right). extracted regions of interest are demonstrated in controls on the left and a patient with MND 
on the right in the tongue (yellow arrows), right biceps (red arrows), right thoracic paraspinal (green arrows) and right anterolateral leg compartment 
encompassing tibialis anterior (blue arrows).
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in right and left TA, respectively (with increases seen in 4/6 indi-
viduals on each side).
Responsiveness was high for global clinical measures and 
moderate for regional clinical measures, electrophysiological 
and radiological change variables.
A post hoc analysis demonstrated that all results reported in 
tables 1–3 retained significance when the three patients with 
progressive muscular atrophy were excluded.
Modelling disease spread
There was no association between muscle relative T2 signal 
change and distance from site of clinical onset.
Muscle area
There were no differences in total or individual muscle area 
at baseline between patients with MND and controls, except 
in the thoracic paraspinals after correction for age and gender 
(see online supplementary table S3). There was no evidence of 
atrophy in any muscles between baseline and 4 months.
dIsCussION
The key results from this study are: (1) patients with MND 
exhibit higher relative T2 signal on muscle MRI than controls; 
(2) higher relative T2 signal in patients with MND is associated 
with clinical weakness and lower electrophysiological motor unit 
numbers in limb muscles; (3) relative T2 signal in bilateral TA 
increases over 4 months in patients with MND and (4) model-
ling pathophysiological mechanisms in vivo is feasible using this 
methodology, but no evidence for contiguous disease spread was 
demonstrated. We conclude that relative T2 signal in muscle 
Figure 3 Box plots illustrating means and sD of relative T2 signal in patients with MND (red) and controls (blue) in the (a) tongue, (B) right biceps, (c) left 
biceps, (D) thoracic paraspinals, (e) right Ta, (F) left Ta and (G) mean all regions. ctrls, controls; L, left; pts, patients; R, right; Ta, tibialis anterior.
Table 2 Associations between muscle relative T2 signal and 
corresponding regional, clinical and electrophysiological measures
Parameter associated 
with relative T2 signal regression coefficient (95% CI) P value
Age 0.001 (−0.002 to 0.004) 0.395
Gender 0.014 (−0.076 to 0.104) 0.749
Days from symptom 
onset
0.00004 (−0.00004 to 0.00012) 0.345 (0.227)
AlsFrs-r −0.009 (−0.017 to –0.001) 0.023 (0.022)
MRC summary score −0.003 (−0.0068 to 0.0001) 0.060 (0.078)
MRC score right biceps −0.017 (−0.064 to 0.030) 0.469 (0.794)
MrC score left biceps −0.079 (−0.147 to –0.011) 0.024 (0.037)
MrC score right TA −0.107 (−0.142 to –0.071) <0.001 (<0.001)
MrC score left TA −0.069 (−0.091 to –0.046) <0.001 (<0.001)
dynamometry right TA −0.005 (-0.007 to –0.002) <0.001 (<0.001)
dynamometry left TA −0.005 (−0.007 to –0.003) <0.001 (<0.001)
MuNIX biceps −0.001 (−0.0020 to –0.0002) 0.015 (0.077)
CMAP biceps −0.027 (−0.049 to –0.005) 0.019 (0.092)
MUSIX biceps −0.0007 (−0.0063 to 0.0048) 0.783 (0.703)
MuNIX TA −0.0018 (−0.0029 to –0.0007) 0.003 (0.001)
CMAP TA −0.055 (−0.082 to –0.028) <0.001 (<0.001)
MUSIX TA −0.0008 (−0.0032 to 0.0015) 0.460 (0.509)
Parameter estimates refer to unadjusted coefficients derived from regression 
models, with 95% CI in parentheses. P values refer to regression models unadjusted 
and, in parentheses, adjusted for age and gender. Significant results after correction 
for multiple comparisons are highlighted in bold.
 ALSFRS-R, amyotrophic lateral sclerosis functional rating scale-revised; 
CMAP, compound muscle action potential; MRC, Medical Research Council; 
MUNIX, motor unit number index; MUSIX, motor unit number size; TA, tibialis 
anterior.
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reflects clinically relevant aspects of MND pathophysiology, and 
the ability to detect longitudinal changes in TA suggests that the 
technique has potential as an objective disease measure.
A biomarker to objectively measure progression over 
short timescales represents a key area of need in MND with 
important implications for future clinical trials.18 Existing trial 
outcome measures such as survival, respiratory failure, change 
in ALSFRS-R, manual muscle power or upper motor neuron 
scores19 have well-documented limitations.20 21 Responsiveness 
was higher for clinical measures than radiological and electro-
physiological changes in our study, due to lower variance, but 
muscle MRI changes were evident in the subgroup of slow 
progressors. Moreover, a higher proportion of patients exhib-
ited radiological change in TA than decreases in MRC scores 
or dynamometry, and correlation analysis suggested that clinical 
weakness and high relative T2 signal reflect complementary but 
distinct aspects of pathophysiology. While CNS biomarkers have 
been well investigated, peripheral biomarkers in MND are an 
exciting new research area. A recently published longitudinal 
study was the first to assess the peripheral nerves in MND using 
diffusion tensor imaging and demonstrated changes reflecting 
axonal degeneration that were associated with clinical and 
electrophysiological deterioration over 6 months.22 Electrical 
impedance myography also appears a promising technique,23 but 
muscle MRI remains largely unexplored. Early studies described 
qualitative morphological changes in the tongue in MND.4 24 A 
small study of the leg muscles identified T2 relaxation, but not 
quantitative T1 or volumetric, changes in a group of 11 patients, 
compared with eight controls, followed over 4 months.5 T2 
signal change is correlated with changes in CMAPs and maximum 
voluntary isometric contraction. There were no further studies 
of muscle MRI in MND for 15 years, until our group reported 
a small pilot study, in which muscle atrophy lagged behind clin-
ical change in four patients over 1-year follow-up.25 Two more 
recent studies were reported on patients with MND who had 
undergone brachial plexus imaging: the first reported abnormal 
appearances of arm muscles in 57%,6 and the second altered 
signal, graded qualitatively, in 70%, 43% and 30% of patients in 
supraspinatus, subscapularis and infraspinatus, respectively.7 No 
previous studies have applied a whole-body MRI methodology 
to study muscle changes in individuals with MND.
Following experimental denervation, reversible high T2 signal 
on muscle MRI is evident from 48 hours after injury,26 associated 
with an increased extracellular fluid space compartment27 28 and 
later with endomysial and perimysial fat deposition between 2 
and 20 weeks.29 In clinical studies, MRI changes appear after 
4 days;30 fatty changes predominate later.31 At the disease stage 
of our patients, it is likely that both fluid compartment shifts and 
sarcolemmal fat replacement related to denervation (evidenced 
by associations with lower MUNIX) are responsible for the 
observed relative T2 changes. However, as we did not obtain 
fat-quantification sequences, we cannot distinguish the relative 
contributions, which is a limitation of our study. In addition, 
T2 measurements were not derived using quantitative relaxom-
etry because of prohibitive scan times for whole-body imaging in 
patients with MND. A recent study of patients with neuropathy/
myopathy obtained quantitative T2, fat fraction and magneti-
sation transfer ratio measurements in 35 min for leg muscles 
alone,16compared with 6 min for whole-body sequences in 
our study (20 min total including set-up, localisers and breath-
holds). Our semiquantitative T2 measurements were adjusted 
using adjacent bone references, which requires an assumption 
Table 3 Longitudinal change in clinical, neurophysiological and MRI parameters in patients with motor neuron disease between baseline and 
4 months
Parameter Change from baseline to 4 months (95% CI) t Value (df) P value srM
AlsFrs-r score (% change from baseline) −3.5 (−5.2 to –1.8); −7.3% (−10.8% to −3.8%) −4.2 (21) <0.001 −0.90
Total MrC score −8.4 (−11.1 to –5.8) −6.6 (21) <0.001 −1.40
MRC score right biceps −0.2 (−0.528 to 0.007) −2.0 (21) 0.057 −0.43
MrC score left biceps −0.4 (−0.7 to –0.1) −2.6 (21) 0.017 −0.55
MrC score right TA −0.8 (−1.3 to –0.3) −3.1 (21) 0.005 −0.67
MrC score left TA −0.9 (−1.5 to –0.3) −3.0 (21) 0.007 −0.64
Dynamometry right TA (lb) −4.6 (−10.6 to 1.4) −1.6 (21) 0.128 −0.34
dynamometry left TA (lb) −8.3 (−15.1 to –1.5) −2.5 (21) 0.019 −0.54
Weight (kg) −0.7 (−2.0 to 0.7) −1.1 (17) 0.302 −0.25
MUNIX biceps −17.4 (−35.0 to 0.1) −2.1 (18) 0.052 −0.48
CMAP biceps −0.7 (−1.3 to –0.2) −2.7 (18) 0.016 −0.61
MUSIX biceps 2.4 (−2.6 to 7.4) 1.0 (18) 0.326 0.23
MuNIX TA −11.0 (−17.9 to –4.0) −3.3 (17) 0.004 −0.78
CMAP TA −0.2 (−0.7 to 0.2) −1.2 (17) 0.239 −0.29
MUSIX TA 4.1 (−6.5 to 14.7) 0.8 (17) 0.428 0.19
T2 signal whole-body average (% change from baseline) −0.01 (−0.04 to 0.02); −2.4% (−5.6% to 10.3%) 0.6 (21) 0.542 0.13
T2 signal from muscle region of clinical onset (% change) 0.02 (−0.02 to 0.05); 4.7% (−0.5% to 14.4%) 1.0 (21) 0.322 0.22
T2 signal tongue (% change) −0.02 (−0.07 to 0.02); −3.4% (−9.9% to 3.0%) −1.1 (21) 0.282 −0.24
T2 signal right biceps (% change) −0.01 (−0.07 to 0.04); −3.1% (−17.5% to 11.3%) −0.5 (21) 0.656 −0.10
T2 signal left biceps (% change) −0.05 (−0.10 to 0.01); −23.1% (−52.7% to  6.6%) −1.6 (21) 0.121 −0.34
T2 signal thoracic paraspinals (% change) 0.05 (−0.10, 0.01); −10.6% (−23.1% to  1.8%) −1.8 (21) 0.091 −0.38
T2 signal right TA (% change) 0.04 (0.01 to 0.07); 10.2% (2.0% to 18.4%) 2.6 (21) 0.017 0.55
T2 signal left TA (% change) 0.03 (0.01 to 0.06); 14.1% (3.4% to 24.9%) 2.7 (21) 0.013 0.58
Parameter estimates and P values refer to paired t-tests. Significant changes after correction for multiple comparisons are highlighted in bold.
ALSFRS-R, amyotrophic lateral sclerosis functional rating scale-revised; CMAP, compound muscle action potential; MRC, Medical Research Council; MUNIX, motor unit number 
index; MUSIX, motor unit number size; SRM, standardised response mean; TA, tibialis anterior.
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that bone signal remains constant. This may not always hold 
true, for example, in menstruation or osteoporosis, but these 
factors were not relevant in our study. Other limitations include 
potential region of interest sampling errors between baseline and 
follow-up, as automated segmentation of whole-body acquisi-
tions remains challenging and final analysis was performed by a 
single rater, heterogeneity in disease course and longer follow-up 
intervals in controls compared with patients. Our patient cohort 
appears slightly younger with a slower rate of progression and 
lower prevalence of bulbar function than the MND population 
in general. Nonetheless, we appear to have captured a biologi-
cally feasible effect in a rapid, low burden and relatively low-cost 
assessment, with the advantage of comprehensive muscle 
sampling that a whole-body acquisition confers.
One such advantage is that mechanistic hypotheses can be 
tested. Clinical and pathological observations suggest that MND 
spread occurs in an anatomically contiguous manner,32 33 with 
prion-like behaviour in experimental models reported.34 We 
found no associations to support this hypothesis in our model. 
This could be because disease spread in our cohort was genuinely 
non-contiguous at spinal level, instead influenced by cortical 
contiguity (which was not assessed), or relate to methodological 
limitations, for example, differential sensitivity to detect disease 
effects in different muscles, non-linear progression patterns or 
insufficient statistical power. Future studies could investigate a 
greater number of muscles in larger cohorts or adopt non-linear 
modelling approaches.
In the present study, muscle abnormalities compared with 
controls, and clinicoradiological associations, were widespread 
and included muscles in which clinical and quantitative neuro-
physiological assessments are challenging, such as thoracic 
paraspinals. In contrast, longitudinal change was only evident 
in TA. Possible reasons include a high prevalence of limb-onset 
disease and more rapid rate of progression of weakness in TA 
compared with biceps, both evident in our cohort. TA may 
represent a good target in future longitudinal studies, regardless 
of site of disease onset. An advantage of whole-body acquisition 
is that other vulnerable muscles may be identified.
In summary, this is the first study to assess whole-body muscle 
MRI in patients with MND, and our findings of biologically 
feasible longitudinal changes are encouraging. Techniques to 
quantify upper motor neuron pathology exist, such as threshold 
Figure 4 Graphs depict longitudinal changes in Ta parameters: (a) percentage relative T2 signal on right, (B) coronal T2-weighted slices from a patient 
with motor neuron disease at baseline and 4 months illustrating an increase in relative T2 signal on the right (yellow arrow), (c) percentage relative T2 signal 
change on left, (D) dynamometry on right, (e) MUNIX tested, (F) dynamometry on left, (G) MRc score on right and (h) MRc score on left. The bold blue 
line represents mean change. asterisks indicate statistically significant change on paired t-tests (p<0.05 corrected for multiple comparisons). MRc, Medical 
Research council; MUNIX, motor unit number index; Ta, tibialis anterior.
group.bmj.com on March 16, 2018 - Published by http://jnnp.bmj.com/Downloaded from 
255Jenkins TM, et al. J Neurol Neurosurg Psychiatry 2018;89:248–255. doi:10.1136/jnnp-2017-316744
Neuromuscular
tracking transcranial magnetic stimulation.35 36 As MND is a 
heterogeneous condition involving both upper and lower motor 
neuron dysfunction, future trials may benefit from a combined 
biomarker approach. Muscle MRI may quantify elements of 
lower motor neuron dysfunction over timescales as short as 
4 months and identify promising candidate muscles to target 
with a formal quantitative T2 relaxometry approach.
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